Albert F. P.
- Country
- Spain
- Department
- Servicio de Oncologia
Research Overview
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
- Phase II Open-Label Evaluation of Sacituzumab Govitecan in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 117 of 275 partner sites.
Specializations
Urothelial Cancer Research
The investigator specializes in advanced treatments for urothelial carcinoma, with particular focus on muscle-invasive bladder cancer and metastatic urothelial cancer. Their research encompasses novel therapeutic combinations including antibody-drug conjugates and immunotherapy approaches.
- HER2-targeted therapies in urothelial cancer
- Perioperative treatment strategies
- Immunotherapy combinations
The investigator explores treatments for both cisplatin-eligible and ineligible patients, advancing personalized therapeutic approaches.
Prostate Cancer Research
The investigator focuses on innovative treatments for various stages of prostate cancer, including metastatic hormone-sensitive and castration-resistant prostate cancer. Their work encompasses targeted therapies and novel drug combinations.
- Hormone therapy resistance
- PTEN-deficient prostate cancer
- DNA damage repair targeted approaches
Research includes investigations into combination therapies and biomarker-driven treatment strategies.
Advanced Cancer Therapeutics
The investigator's expertise extends to developing targeted therapies and combination treatments for advanced solid tumors. Their work includes evaluation of novel therapeutic agents and immunotherapy combinations.
- Antibody-drug conjugates
- Multimodal treatment approaches
- Precision medicine strategies
The research focuses on improving treatment outcomes through innovative therapeutic combinations and personalized approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.